- Home
- MCGA vs CNTX Comparison
MCGA vs CNTX Comparison
Compare MCGA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.43
Company Overview
Basic Information| Metric | MCGA | CNTX |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 209.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCGA | CNTX |
|---|---|---|
| Price | $10.13 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 327.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $0.49 |
| 52 Week High | $11.88 | $2.85 |
Technical Indicators
Market Signals| Indicator | MCGA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 66.84 |
| Support Level | $10.15 | $2.09 |
| Resistance Level | $10.16 | $2.85 |
| Average True Range (ATR) | 0.01 | 0.30 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 62.73 |
Price Performance
Historical Comparison MCGA
CNTX
About MCGA Yorkville Acquisition Corp. Class A Ordinary Share
Yorkville Acquisition Corp is a blank check company.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.